Response Genetics Company Executives
| RGDXQ Stock | USD 0.0001 0.00 0.00% |
Discussion of Response Genetics' management performance can provide insight into the enterprise performance.
Response |
| Symbol | RGDXQ |
| Name | Response Genetics |
| Type | Pink Sheet |
| Country | United States |
| Exchange | PINK |
Information on Response Genetics Leadership is currently not available.
If you believe this information is not accurate please let us know and we will check it out. Check all delisted instruments across multiple markets.Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Thematic Opportunities
Explore Investment Opportunities
Response Genetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6788) % which means that it has lost $0.6788 on every $100 spent on assets. This is way below average. Response Genetics' management efficiency ratios could be used to measure how well Response Genetics manages its routine affairs as well as how well it operates its assets and liabilities.Response Genetics Workforce Comparison
Response Genetics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 208. Response Genetics totals roughly 96.0 in number of employees claiming about 46% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.86) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.82) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.82. Response Genetics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Response Genetics Price Series Summation is a cross summation of Response Genetics price series and its benchmark/peer.
About Response Genetics Management Performance
The success or failure of an entity such as Response Genetics often depends on how effective the management is. Response Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Response management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Response management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. RESPONSE GENETICS operates under Diagnostics Research classification in the United States and is traded on PNK Exchange. It employs 96 people.
Additional Tools for Response Pink Sheet Analysis
When running Response Genetics' price analysis, check to measure Response Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Response Genetics is operating at the current time. Most of Response Genetics' value examination focuses on studying past and present price action to predict the probability of Response Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Response Genetics' price. Additionally, you may evaluate how the addition of Response Genetics to your portfolios can decrease your overall portfolio volatility.